Cargando…
The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoid neoplasm among adults,and approximately 30–40% of patients will experience relapse while 5–10% will suffer from primary refractory disease caused by different mechanisms, including treatment-induced resistance. For refra...
Autores principales: | Nesic, Marijana, Sønderkær, Mads, Brøndum, Rasmus Froberg, El-Galaly, Tarec Christoffer, Pedersen, Inge Søkilde, Bøgsted, Martin, Dybkær, Karen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286604/ https://www.ncbi.nlm.nih.gov/pubmed/34275438 http://dx.doi.org/10.1186/s12885-021-08556-3 |
Ejemplares similares
-
Implementing the FAIR Data Principles in precision oncology: review of supporting initiatives
por: Vesteghem, Charles, et al.
Publicado: (2019) -
Development of a Precision Medicine Workflow in Hematological Cancers, Aalborg University Hospital, Denmark
por: Bødker, Julie S., et al.
Publicado: (2020) -
MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index
por: Due, Hanne, et al.
Publicado: (2020) -
Patient-reported outcomes in patients with hematological relapse or progressive disease: a longitudinal observational study
por: Sommer, Mia, et al.
Publicado: (2021) -
hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine
por: Falgreen, Steffen, et al.
Publicado: (2016)